GlassScriptPhysician profile
Mark Thomas Edney
NPI 1184684789
$28,474.85
in general payments reported to CMS, 2019-2025
30 companies · $875 in 2025
The $875 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $273 · 2021: $14K · 2022: $4,698 · 2023: $7,107 · 2024: $1,251 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,500 · Food and Beverage: $3,622 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,500.00 |
| Food and Beverage | $3,621.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $21,621.41 | 2021-2025 | Prolaris, Genesight |
| Teleflex LLC | $2,362.38 | 2021-2025 | Urolift, Barrigel |
| Progenics Pharmaceuticals, INC. | $617.72 | 2022-2025 | Pylarify |
| Urogen Pharma, INC. | $553.97 | 2021-2024 | Jelmyto |
| Dendreon Pharmaceuticals LLC | $496.70 | 2019-2025 | Provenge |
| Janssen Biotech, INC. | $429.40 | 2023-2025 | Erleada, Akeega |
| Abbvie INC. | $413.54 | 2019-2025 | Botox |
| Sumitomo Pharma America, INC. | $213.87 | 2023-2025 | Orgovyx, Gemtesa |
| Boston Scientific Corporation | $202.17 | 2019-2024 | Ams 700, Solyx Sis System, Ams 800 Artificial Urinary Sphincter |
| Olympus America INC. | $170.90 | 2023-2024 | Itind System |
| Coloplast Corp | $162.06 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $160.44 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $156.12 | 2020-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $153.51 | 2019-2025 | |
| Immunitybio, INC. | $135.18 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $134.54 | 2019-2024 | Xtandi |
| Neotract INC. | $124.64 | 2019-2020 | |
| Medtronic, INC. | $109.18 | 2023 | Interstim |
| Procept Biorobotics Corporation | $59.51 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $24.49 | 2022 | |
| Allergan, INC. | $22.03 | 2022 | |
| Amgen INC. | $20.84 | 2020 | |
| Tempus Ai, INC | $19.74 | 2024 | |
| Foundation Medicine, INC. | $19.01 | 2023 | Foundationone Cdx |
| Accord Healthcare, INC. | $18.98 | 2023 | |
| Novartis Pharmaceuticals Corporation | $17.91 | 2023 | |
| Telix Pharmaceuticals | $15.61 | 2024 | Illuccix |
| Photocure INC | $14.65 | 2021 | |
| Myovant Sciences INC. | $13.02 | 2021 | |
| Urovant Sciences INC | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Edney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.